Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PolyPeptide Group AG (PPGN.SW)
CHF47.10
-0.10 (-0.21%)
CH SIX Healthcare Drug Manufacturers - Specialty & Generic
Address
Dammstrasse 19 6300
Baar, CH
Baar, CH
CEO
Juan Jose Gonzalez
Website
polypeptide.com
IPO
2021-04-28
ISIN CH1110760852
Also trades on
London Stock Exchange · 0AAJ.L (CHF)
Swiss Exchange · PPGN.SW (CHF)
Description
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CHF47.10
-0.10 (-0.21%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
76.9K
Beta
1.04
Float Shares
12.96M
Free Float %
39.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.81% | -1.69% | -0.66% | +47.47% | +49.80% | +57.92% | +83.54% | +61.14% | -49.89% | -39.36% | -39.36% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
47.10
Ratings Trend (MoM)
83% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
Quality scores
Altman Z-Score
3.02
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+15.7% ★ Q4'25: +18.1% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-8.5% Q4'25: +130.8% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+7.2% Q4'25: -14.1% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+1.9% Q4'25: +9.1% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+1.9% Q4'25: +12.3% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q4'25: +0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.94× Q4'25: 0.81× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 3 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
282.13M
est: 290.48M (-2.9%)
|
280.98M
est: 282.51M (-0.5%)
|
320.37M
est: 335.65M (-4.6%)
|
338.69M
est: 347.40M (-2.5%)
|
391.87M
est: 391.00M (+0.2%)
|
473.22M
463.28M – 479.91M
+21.0% YoY
|
539.91M
531.58M – 553.68M
+14.1% YoY
|
626.44M
615.14M – 639.09M
+16.0% YoY
|
690.89M
678.43M – 704.85M
+10.3% YoY
|
| EBITDA |
83.35M
est: 40.57M (+105.4%)
|
35.72M
est: 39.46M (-9.5%)
|
-22.15M
est: 36.97M (-159.9%)
|
28.42M
est: 38.26M (-25.7%)
|
44.42M
est: 43.06M (+3.1%)
|
52.12M
51.03M – 52.86M
+21.0% YoY
|
59.47M
58.55M – 60.98M
+14.1% YoY
|
69.00M
67.75M – 70.39M
+16.0% YoY
|
76.09M
74.72M – 77.63M
+10.3% YoY
|
| EBIT |
62.67M
est: 15.24M (+311.2%)
|
9.66M
est: 14.82M (-34.9%)
|
-52.62M
est: 6.61M (-895.8%)
|
-4.30M
est: 6.84M (-162.8%)
|
7.41M
est: 7.70M (-3.8%)
|
9.32M
9.13M – 9.45M
+21.0% YoY
|
10.64M
10.47M – 10.91M
+14.1% YoY
|
12.34M
12.12M – 12.59M
+16.0% YoY
|
13.61M
13.36M – 13.88M
+10.3% YoY
|
| Net Income |
47.26M
est: 45.22M (+4.5%)
|
7.77M
est: 13.48M (-42.4%)
|
-51.44M
est: -29.63M (-73.6%)
|
-19.56M
est: -13.16M (-48.6%)
|
-21.31M
est: -17.24M (-23.6%)
|
18.08M
8.21M – 33.74M
+204.9% YoY
|
45.01M
32.27M – 46.94M
+148.9% YoY
|
65.52M
62.29M – 68.76M
+45.6% YoY
|
93.34M
91.15M – 95.79M
+42.5% YoY
|
| SGA |
32.50M
est: 29.25M (+11.1%)
|
40.63M
est: 28.45M (+42.8%)
|
18.76M
est: 34.95M (-46.3%)
|
21.33M
est: 36.18M (-41.0%)
|
54.61M
est: 40.72M (+34.1%)
|
49.28M
48.24M – 49.97M
+21.0% YoY
|
56.22M
55.36M – 57.66M
+14.1% YoY
|
65.23M
64.06M – 66.55M
+16.0% YoY
|
71.94M
70.65M – 73.40M
+10.3% YoY
|
| EPS |
1.47
est: 1.37 (+7.2%)
|
0.24
est: 0.40 (-39.6%)
|
-1.56
est: -0.91 (-72.4%)
|
-0.59
est: -0.40 (-48.1%)
|
-0.64
est: -0.52 (-22.6%)
|
0.65
0.25 – 1.02
+224.2% YoY
|
1.23
0.98 – 1.42
+90.2% YoY
|
1.99
1.89 – 2.08
+61.6% YoY
|
2.83
2.76 – 2.90
+41.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
92.55M
OE per share TTM
2.76
Owner's Yield
7.40%
Maintenance CapEx ratio
467.48%
Maint CapEx / Avg PPE
98.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 62 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis International Small Cap Value ETF AVDV | 0.12% | 22.66M | 0.36% |
| 2 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.09% | 1.07M | 0.40% |
| 3 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.06% | 1.98M | 0.30% |
| 4 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.06% | 191.0K | 0.23% |
| 5 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.06% | 191.0K | 0.23% |
| 6 | State Street SPDR S&P International Small Cap ETF GWX | 0.05% | 396.9K | 0.40% |
| 7 | iShares MSCI Europe Small-Cap ETF IEUS | 0.04% | 75.6K | 0.41% |
| 8 | Avantis Global Small Cap Value UCITS ETF AVGS.L | 0.04% | 428.5K | 0.39% |
| 9 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.03% | 2.40M | 0.10% |
| 10 | Avantis International Small Cap Equity ETF AVDS | 0.03% | 106.7K | 0.30% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
5.4K
Shares Outstanding
33.01M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Juan Jose Gonzalez | Chief Executive Officer | 2M | male |
| Christina Del Vecchio | Chief Legal Officer & Corporate Secretary | — | female |
| Christophe Chevalier | Head of Technical Department - Braine | — | — |
| Krister Svard | Chief Information Security Officer & Global IT Services VC | — | — |
| Michael Staheli | Head of Investor Relations & Corporate Communications | — | male |
| Monika Casanova | Chief Human Resources Officer | — | female |
| Olivier Ludemann-Hombourger | Director of Global Innovation & Technology | — | male |
| Rene Vestergaard | Director of Corporate Finance | — | — |
| Tim Brandl | Interim CFO and Director of Investor Relations, Financial Planning & Analysis | — | male |
| Andreas Liese | Corporate Compliance Manager | — | — |
| Trishul Shah | Interim Director Global Sales & Marketing | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PPGN.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
